Dengue Moment
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
The World Health Organization (WHO) has donated 2,160 doses of Ebola trial vaccine to Uganda to evaluate the efficacy of the vaccine in combating the virus which in the recent outbreak has killed a health worker in Kampala, the country's capital.
Indonesia is developing a new Tuberculosis (TB) vaccine to strengthen the fight against TB, which has claimed an average of 150,000 lives annually.
The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Specifically, the team compared the immune responses in people who were protected against CMV infection after receiving the older vaccine.
For years, the human papillomavirus (HPV) vaccine has been widely recognized as a crucial weapon against cervical cancer in women.
India’s billionaire "vaccine prince" Adar Poonawalla has reached a deal for London’s most expensive home sale of the year, agreeing to pay about 138 mn pound for a 25,000 square foot Mayfair mansion, media reports said.
The R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India has been recommended for use by the World Health Organisation (WHO) after meeting required safety, quality and effectiveness standards.
The daily positivity rate presently stands at 2.49 per cent, while the weekly positivity rate is at 3.46 per cent.
The Health Ministry said that India's active caseload currently stands at 9,433. The total recoveries are at 4,41,63,883 with 1,051 recoveries in the last 24 hours.
